NCT03139305进行中（未招募）1 期
Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects
AdventHealth Translational Research Institute1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2017年10月24日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Effects of continuous IV infusion of glucagon versus placebo
研究概览
简要总结
The main purpose of this study is to examine the effect of prolonged (72 hour) administration of glucagon compared to placebo on energy expenditure in healthy, non-diabetic, obese subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 18-55 years, inclusive.
- •Body Mass Index (BMI) ≥27 to ≤45 kg/m2 and body weight <450 lbs.
- •Stable body weight for 3 months (self-reported loss/gain <5%).
- •Judged to be non-diabetic per the American Diabetes Association guidelines:
- •fasting plasma glucose <126 mg/dL [7.0 mmol/L] and
- •HbA1c <6.5% [48 mmol/mol]) and
- •in good health on the basis of medical history, physical examination (PE), electrocardiogram (ECG), and normal laboratory values obtained from Screening visit labs.
- •Understands the procedures and agrees to participate in the study program by giving written informed consent, and is willing to comply with the trial restrictions.
- •Willing to avoid alcohol consumption for 48 hours prior to the inpatient study visit.
- •Willing to avoid consumption of caffeine and caffeinated beverages for 24 hours prior to the inpatient study visit.
- •Willing to avoid strenuous physical activity for 72 hours prior to the inpatient study visit.
- •Exclusion Criteria
- •Treatment with any medication known to significantly impact body weight or energy metabolism (e.g., weight loss medications, atypical antipsychotics) within 3 months prior to screening except for stable physiological hormone replacement therapy (i.e., thyroid hormone, estrogen).
- •Treatment with a selective serotonin reuptake inhibitor, a medication for depression or apomorphine within one week prior to screening due to interaction with Zofran.
- •History of bariatric surgery.
- •Current liver, renal, pulmonary, cardiac, oncologic, metabolic, gastrointestinal, or hematologic disease which the Investigator believes is clinically significant, including:
- •a. Liver disease or liver injury as indicated by abnormal liver function tests (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, serum bilirubin) >3 × upper limit of normal (ULN), or history of hepatic cirrhosis.
- •Impaired renal function as indicated by an estimated glomerular filtration rate (eGFR) <60 mL/min or urine albumin-to-creatinine ratio >35 mg/mmol.
- •Significant cardiovascular disease, including Class III or greater congestive heart failure (CHF), coronary artery disease, second degree or greater heart block, or clinically significant arrhythmias; baseline second degree or greater heart block or prolonged QT syndrome (QTc interval ≥470 msec); or any major cardiovascular event within the last 3 years (including myocardial infarction [MI], transient ischemic attack, cerebrovascular accident [CVA], angina, and hospitalization due to CHF,transient ischemic attack, and CVA).
- •Metabolic, or other endocrine disorders, including diagnosis of type 1 or type 2 diabetes mellitus [HbA1c ≥6.5%]), inadequately treated hyperthyroidism (thyroid stimulating hormone [TSH] below normal range) or hypothyroidism (TSH >ULN <10 U/mL and symptomatic or TSH >10 U/mL), Cushing's disease/syndrome, Addison's disease, hypogonadism, or genetic disorders linked to obesity.
- •History of irritable bowel disease, recurrent nausea, or vomiting.
- •Anemia (hemoglobin <12 g/dL in males, <11 g/dL in females).
- •History of dyslipidemia: Fasting triglycerides (TG) >500 mg/dL and low-density lipoproteins (LDL) >250 mg/dL.
- •Self-reported history of infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
- •History of recurrent sleep disturbances and/or prone to sleep disturbances based on lifestyle or employment (e.g., variable work schedule, overnight shift work, etc.).
- •Diagnosis of sleep apnea with or without use of continuous positive airway pressure/BiPAP/AutoPAP.
- •Major surgery within 3 months prior to screening.
- •Blood donation within 4 weeks prior to screening.
- •Participation in another investigational trial within 4 weeks prior to screening. The 4 week window will be derived from the date of the last trial medication and/or blood collection in a previous trial and/or adverse event (AE) related to trial drug screening of the current trial.
- •Use of illicit drugs or nicotine-containing products within 3 months prior to screening.
- •Poor intravenous (IV) access.
- •Blood pressure <100/50 mmHg or ≥160/100 mmHg during screening.
- •Heart rate ≥100 bpm during screening.
- •Fasting plasma glucose <60 mg/dL or ≥126 mg/dL during screening.
- •Female subjects who are, or intend to become, pregnant during the course of this study, are currently breastfeeding, or women of child-bearing potential (WOCBP) who refuse to use at least one method of birth control (oral contraceptives, intrauterine device, implanted or injectable contraceptives, abstinence).
- •Translational Research Institute for Metabolism and Diabetes (TRI-MD) staff member or immediate relative of TRI-MD staff members directly involved
- •History of any illness or condition that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the subject by study participation.
排除标准
- 未提供
研究组 & 干预措施
Glucagon Low Dose
Active Comparator
干预措施: Glucagon (Drug)
Glucagon High Dose
Active Comparator
干预措施: Glucagon (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Effects of continuous IV infusion of glucagon versus placebo
时间窗: 72 hours
Overall well-being will be measured by administering a questionnaire with a scale from none to severe.
Energy Expenditure
时间窗: 24 hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Safety Study of Repeated Doses of Glucagon on Animal Starch in the LiverType 1 Diabetes MellitusNCT01986231Legacy Health System12
终止
不适用
Efficacy of Glucagon In the Prevention of Hypoglycemia During Mild ExerciseType 1 Diabetes MellitusNCT03217175Massachusetts General Hospital22
进行中（未招募）
不适用
Investigation of the duration of the effect of the hormone glucagon on the glucose production of the liver in patients with diabetesDiabetes mellitus type 1MedDRA version: 17.1Level: LLTClassification code 10012608Term: Diabetes mellitus insulin-dependentSystem Organ Class: 100000004861EUCTR2015-000322-11-ATMedizinische Universität Graz; Universitätsklinik für Innere Medizin; Abteilung für Endokrinologie und Stoffwechsel
已完成
4 期
Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?Metabolic DisturbanceFeasibilityOverweight and ObesityLiraglutideMental DisorderNCT04781998Anders Fink-Jensen, MD, DMSci24
招募中
不适用
Impact of ß-glucan Supplementation on Subjective Appetite and Gastrointestinal Appetite Hormones.Overweight and ObesityNCT05981404University of Glasgow25